Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.

Despite an apparent dose-dependent effect on VAS, comparison of the effect size between the 2 groups did not reach statistical significance at any of the time points ( Figure 3B ).

also in 111,027 other papers